imported>Felipe Gerhard |
imported>David E. Volk |
| Line 3: |
Line 3: |
|
| |
|
| '''Clindamycin''' is an [[antibiotic]] drug, in the [[lincomycin]] class, used to treat infections. It is a semisynthetic version of lincomycin. It is used to treat [[streptococci]], [[pneumococci]] and [[staphylococci]]. | | '''Clindamycin''' is an [[antibiotic]] drug, in the [[lincomycin]] class, used to treat infections. It is a semisynthetic version of lincomycin. It is used to treat [[streptococci]], [[pneumococci]] and [[staphylococci]]. |
|
| |
| == Chemistry ==
| |
| The IUPAC chemical name of clindamycin is (2S,4R)-N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide. It has chemical formula C<sub>18</sub>H<sub>33</sub>ClN<sub>2</sub>O<sub>5</sub>S, giving it a molecular mass of 424.9830 g/mol.
| |
|
| |
| == Usage ==
| |
| Clindamycin, a relatively old drug, is being found valuable in the treatment of methicillin-resistant ''[[Staphylococcus aureus]]'' (MRSA), an organism that causes significant [[nosocomial]] infection, which, increasingly, is considered a [[medical error]] for which third-party payor will not reimburse. While improvement in infection control technique are key to preventing hospital-acquired MRSA infection, there will be infections and they will need to be treated. <ref name=Gorwitz>{{citation
| |
| | author = Gorwitz RJ, Jernigan DB, Powers JH, Jernigan JA, and Participants in the CDC Convened
| |
| Experts’ Meeting on Management of MRSA in the Community
| |
| | id = Gorwitz
| |
| | title = Strategies for clinical management of MRSA in the community: Summary of an experts’ meeting convened by the Centers for Disease Control and Prevention
| |
| | year = 2006
| |
| | url = http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html}}</ref>
| |
|
| |
| Clindamycin may be associated with a higher incidence of ''[[Clostridium difficile]]''-associated disease (CDAD), including [[pseudomembranous enterocolitis]]. Additional laboratory testing may be appropriate to evaluate the possibility of induced clindamycin resistance in MRSA. <ref>Gorwitz, p. 7</ref> Whenever clindamycin is used, especially in oral form with outpatients, patients should be cautioned to report, immediately, episodes of diarrhea.
| |
| == Synonyms and brand names ==
| |
| ''Synonyms''
| |
| * Clindamycin HCl
| |
| * Clindamicina
| |
| * Clindamycin Hydrochloride
| |
| * Clindamycin Phosphate
| |
| * Clindamycine
| |
| * Clindamycine
| |
| * Clindamycinum
| |
|
| |
| ''Brand Names''
| |
| * Chlolincocin®
| |
| * Cleocin®
| |
| * Cleocin HCl®
| |
| * Cleocin Pediatric®
| |
| * Cleocin Phosphate®
| |
| * Cleocin T®
| |
| * Cleocin T® Gel
| |
| * Cleocin T® Lotion
| |
| * Cleocin T® Topical Solution
| |
| * Clinda-Derm®
| |
| * Clindagel®
| |
| * Clindesse®
| |
| * Clindets®
| |
| * Clinimycin®
| |
| * Dalacin®
| |
| * Dalacin C®
| |
| * Dalacin C® Flavored Granules
| |
| * Dalacin C® Phosphate
| |
| * Dalacin T® Topical Solution
| |
| * Evoclin®
| |
| * Sobelin®
| |
|
| |
| ==References==
| |
| <references/>
| |
